Key Takeaways
- Adjusted earnings per share reached $2.91, surpassing the analyst consensus of $2.42
- Fiscal 2026 adjusted EPS guidance range of $12.40-$12.60 exceeds Wall Street’s $12.08 projection
- Quarterly revenue climbed 6% to $63.67 billion but fell short of the $65.15 billion estimate
- Pharmaceutical division revenue advanced 6%; medical products segment declined 2%
- CAH shares slipped 0.8% during Tuesday’s premarket session
Cardinal Health delivered a combination of hits and misses in its fiscal fourth-quarter results Tuesday, though management’s upbeat annual forecast provided a silver lining for market watchers.
The company’s adjusted earnings per share landed at $2.91 for the period, exceeding Wall Street’s $2.42 projection. This figure incorporated a $0.31 benefit from tariff-related refunds, bringing the core operational result to $2.60 per share.
Total revenue increased 6% from the prior-year quarter to reach $63.67 billion. However, this fell below analysts’ target of $65.15 billion.
Shares of CAH traded 0.8% lower in premarket activity Tuesday morning.
Using generally accepted accounting principles, net income totaled $398 million, translating to $1.70 per share. This marks a substantial improvement from the year-ago quarter’s $239 million, or $1.00 per share.
Divisional Results
The pharmaceutical division posted 6% revenue growth, propelled by increased order volumes from current clients and robust generic medication sales.
In contrast, the global medical products and distribution operation emerged as the underperformer. Sales in this segment contracted 2%, weighed down by reduced distribution volumes and the impact of anticipated tariff refund reimbursements flowing back to customers.
This divergence in segment trends deserves attention as Cardinal pursues expansion in emerging market opportunities.
Forward Outlook Tops Expectations
Looking to the upcoming fiscal year, Cardinal Health projected adjusted earnings per share between $12.40 and $12.60. This guidance implies year-over-year growth of 13% to 15% and substantially exceeds the FactSet analyst consensus of $12.08.
Management anticipates pharmaceutical revenue will expand 3% to 5%, while the medical products and distribution division is expected to grow 2% to 4%.
This forward-looking view incorporates recent strategic initiatives in the home healthcare space, particularly the Strive Medical acquisition and a planned transaction to acquire AdaptHealth’s diabetes operations.
Additionally, Cardinal announced it has secured a new $4 billion revolving credit facility extending through 2031. This arrangement consolidates and replaces three existing credit lines.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
